ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Altered Erythrocyte Function via TLR9-ox-mtDNA Binding Links Mitochondrial Oxidative Damage to Systemic Inflammation in Multiple Sclerosis.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS), an autoimmune disorder of the central nervous system(CNS), is charactered by neuroinflammation and neurodegeneration. Red blood cells (RBCs) are the most abundant cells in circulation, yet their immunological roles remain poorly understood, especially in neuroimmunology. Here, we explored the role and mechanism of erythrocytes in linking CNS pathology to systemic inflammation in MS, by combining clinical epidemiology and experimental model validation. In UK Biobank (1,056 MS patients; 501,314 controls), MS patients exhibited significantly altered erythrocyte function. Notably, lower baseline erythrocyte counts were inversely associated with MS incidence. Our clinical cohort of 110 relapsing-remitting MS (RRMS) patients revealed progressive declines in RBC parameters (RBC counts, hemoglobin, hematocrit) which associated with disease duration and worse EDSS scores. In RRMS patients, RBCs proteomics and flow cytometry revealed TLR9 membrane translocation and CD47 downregulation. Ox-mtDNA-bound erythrocytes were more phagocytosed by macrophages, which subsequently triggered inflammatory activation and type I interferon responses. These findings were corroborated in the EAE model, where CNS-derived ox-mtDNA was found bound to erythrocyte TLR9, accompanied by compensatory erythropoiesis and interferon-β-driven inflammation. Treatment with the mitochondrial-targeted antioxidant MitoQ effectively normalized erythrocyte TLR9/CD47 expression, reduced ox-mtDNA release, and alleviated neuroinflammation. Collectively, our work defines a novel erythrocyte-TLR9-ox-mtDNA axis that links CNS mitochondrial damage to peripheral inflammation in MS. By integrating clinical cohort data with proteomics and experimental models, we establish erythrocyte pathology as a central feature of MS and highlight the therapeutic potential of targeting mitochondrial dysfunction to disrupt this cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.